L'etude clinique du mois. Essais de preservation des cellules B a la phase initiale du diabete de type 1: resultats negatifs avec l'insuline retard, mais prometteurs avec un anticorps monoclonal anti-CD3.
Philips, Jean-Christophe; Scheen, André
2002 • In Revue Médicale de Liège, 57 (6), p. 413-7
Adult; Antibodies, Monoclonal/therapeutic use; Antigens, CD3/immunology; Diabetes Mellitus, Type 1/prevention & control; Disease Progression; Genetic Predisposition to Disease; Humans; Hypoglycemic Agents/administration & dosage/pharmacology; Injections, Subcutaneous; Insulin, Long-Acting/administration & dosage/pharmacology; Islets of Langerhans/cytology/pathology; Randomized Controlled Trials as Topic; Risk Factors
Abstract :
[en] Type 1 diabetes is an autoimmune disease leading to a progressive exhaustion of the insulin secretion and a destruction of the B-cells. Attempts of preservation of insulin-producing B-cells can be performed at an early, most often silent, stage of the disease in well-selected at high risk subjects or during the period immediately following the clinical diagnosis based upon classical signs of hyperglycaemia. In the "Diabetes Prevention Trial-Type 1", the prophylactic subcutaneous administration of low-dose ultralente insulin was not able to prevent the development of type 1 diabetes nor to preserve residual insulin secretion in young relatives at very high-risk of diabetes, selected upon genetic, immunological and metabolic criteria. In contrast, a pilot randomized trial shows that a treatment with a nonactivating humanized monoclonal antibody against CD3 mitigates the deterioration in insulin production and improves metabolic control, with lower dose of exogenous insulin, during the first year of type 1 diabetes mellitus in 9 out of 12 treated patients. Besides a better understanding of the natural history of the disease, these clinical trials open new perspectives for prevention of type 1 diabetes mellitus, currently assessed by the Belgian Diabetes Registry.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Philips, Jean-Christophe ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
French
Title :
L'etude clinique du mois. Essais de preservation des cellules B a la phase initiale du diabete de type 1: resultats negatifs avec l'insuline retard, mais prometteurs avec un anticorps monoclonal anti-CD3.
Alternative titles :
[en] Clinical study of the month. Attempt at preservation of B cells during the initial phase of type 1 diabetes: negative results with ultralente insulin, but promising results with an anti-CD3 monoclonal antibody
Publication date :
2002
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Geenen V. (1996) Le diabète insulinodépendant. Rev Med Liège 51:684-694.
Atkinson M.A., Eisenbarth G.S. (2001) Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 358:221-229.
Philips J.C., Letiexhe M.R., Paquot N. (1997) Comment j'explore .. Un patient avec diabète de type 1 inaugural ou à risque de développer la maladie. Rev Med Liège 52:363-366.
Bingley P.J., Bonifacio E., Ziegler A.-G. (2001) Proposed guidelines on screening for risk of type 1 diabetes. Diabetes Care 24:398.
Gorus F.K. (1997) Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Diabetes/Metab Rev 13:247-274.
(1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial: A randomized, controlled trial. Ann Intern Med 128:517-523.
Atkinson M.A., Leiter E.H. (1999) The NOD mouse model of type 1 diabetes: As good as it gets?. Nat Med 5:601-604.
Gardner S.G., Gale E.A.M., Williams A.J.K. (1999) Progression to diabetes in relatives with islet autoantibodies: Is it inevitable?. Diabetes Care 22:2049-2054.
(2000) Prevention of type 1 diabetes mellitus. Diabetes Care 23(SUPPL. 1).
Naik R.G., Palmer J.P. (1999) Preservation of beta-cell function in type 1 diabetes. Diabetes Rev 7:154-182.
Gale E.A.M. (2002) Can we change the course of beta-cell destruction in type 1 diabetes?. N Engl J Med 346:1740-1742.
Kolb H., Gale E.A.M. (2001) Does partial preservation of residual B-cell function justify immune intervention in recent onset type 1 diabetes?. Diabetologia 44:1349-1353.
(2002) Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346:1685-1691.
Herold K.C., Hagopian W., Auger J.A. (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698.
Scheen A.J., Philips J.-C. (2001) Insulinothérapie pour prévenir le diabète de type 1 chez des sujets apparentés à haut risque: Résultats négatifs du "Diabetes Prevention Trial-Type 1 ". Rev Med Liège 56:536-538.
Luyckx F.L., Scheen A.J. (2001) Comment j'explore .. Les anomalies du métabolisme glucidique, de l'insulinosé-crétion et de la sensibilité à l'insuline avec une hyperglycémie provoquée par voie orale. Rev Med Liège 55:881-885.
Atkinson M.A., Maclaren N.K., Luchetta R. (1990) Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39:933-937.
Keller R.J., Eisenbarth G.S., Jackson R.A. (1993) Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 341:927-928.
Chaillous L., Lefèvre H., Thivolet Ch. (2000) Oral insulin administration and residual B-cell function in recent-onset type 1 diabetes: A multicentre randomised controlled trial. Lancet 356:545-549.
Pozzilli P., Pitocco D., Visalli N. (2000) No effect of oral insulin on residual beta-cell function in recent-onset type 1 diabetes (the IMDIAB VII). Diabetologia 43:1000-1004.
Gorus F., Goubert P., Semakula C. (1997) IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impeding diabetes in their siblings. Diabetologia 40:95-99.
Luyckx F., Delcour S., Philips J.C., Scheen A.J. (2000) Le dosage des auto-anticorps anti-GAD et anti-IA2: Une aide au diagnostic précoce du diabète de type 1. Rev Med Liège 55:169-175.
Scheen A.J., Letiexhe M.R., Geronooz I. (2002) L'hyperglycémie post-prandiale. II. Approches thérapeutiques médicamenteuses. Rev Med Liège 57:196-201.
Chatenoud L., Thervet E., Primo J., Bach J.F. (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 91:123-127.
Herold K.C., Bluestone J.A., Montag A.G. (1992) Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 41:385-391.
Chatenoud L. (2001) Restoration of self-tolerance is a feasible approach to control ongoing beta-cell specific autoreactivity: Its relevance for treatment in established diabetes and islet transplantation. Diabetologia 44:521-536.